Thank you so mcuh @stoverlab.bsky.social for the phenomenal keynote lecture-- you have built an incredible translational research infrastructure and team! It was wonderful to have you back in Boston! @dfcibreastonc.bsky.social

Don't miss this recent review outlining practical treatment strategies and novel therapies in the PI3K/AKT/mTOR pathway in HR+/HER2- advanced #BreastCancer 🔓 pubmed.ncbi.nlm.nih.gov/39674130/ @antgiordanomd.bsky.social @drtimothyerick.bsky.social @stolaney1.bsky.social @drsarahsammons.bsky.social

Congratulations all!! @stolaney1.bsky.social @lymphomadoc.bsky.social @ryannipp.bsky.social and more! #FASCO

very important (but negative) trial on cdk46i in mTNBC. huge shout-out to @stolaney1.bsky.social and Shom Goel for conducting this trial👍 @oncoalert.bsky.social #bcsm

Don't miss this recent Current Oncology Reports review on #AntibodyDrugConjugates in #BreastCancer: The Road Towards Biologically-Informed Selection and Sequencing pubmed.ncbi.nlm.nih.gov/39786525/ @ptarantinomd.bsky.social @ilanaschlam.bsky.social @stolaney1.bsky.social #AnaGarridoCastro

Dr. Paolo Tarantino (@ptarantinomd.bsky.social) and Dr. Sara Tolaney (@stolaney1.bsky.social) discuss efforts to create consensus based #BreastCancer Treatment Guidelines, which are meant to encourage uniform, evidence-based practice. Read here ⬇️ physicianresources.dana-farber.org/symposium/br...

Join Dr. Sara Tolaney (@stolaney1.bsky.social) tomorrow at #SABCS24 for an insightful #CareerDevelopment session, focused on early funding for research. Dr. Tolaney will discuss the importance of having foundation and community program support. 🗓️ Dec 10th ⏰12:00–1:45 pm CST (1:00 pm EST) 📍Rm 221ABC

Dr. Sara Tolaney (@stolaney1.bsky.social) will moderate the #SABCS24 poster spotlight session 3 on novel therapeutics in #BreastCancer on Wed Dec 11th – don’t miss it! 🗓️ Wednesday, December 11th ⏰ 7:00 – 8:30 am CST (8:00 – 9:30 am EST) 📍 Stars at Night 1-2

Dr. Sara Tolaney (@stolaney1.bsky.social) offered great tips and strategies for obtaining research funding from foundations and community programs in the #SABCS24 Career Development Session. Biggest take away: Start early! @danafarber.bsky.social

Thank you all for stepping by and chatting with me yesterday. Thanks to @dfcibreastonc.bsky.social , my mentor @stolaney1.bsky.social , and all the co-authors for this great opportunity 😊 #SABCS2024 @sabcs.bsky.social

Meet Dr. Stefania Morganti, an Advanced Fellow at the Breast Oncology Center at @danafarber.bsky.social. Dr. Morganti earned her MD at the University of Pavia and specialized in medical oncology. Her research is aimed at developing patient-centered approaches to advance #BreastCancer treatment.

Check out this recent review on the role of #AntibodyDrugConjugates in the treatment of patients with #BreastCancerBrainMetastases. pubmed.ncbi.nlm.nih.gov/39529890/ #StaceyPan @drsarahsammons.bsky.social @nlinmd.bsky.social @stolaney1.bsky.social @ilanaschlam.bsky.social @ptarantinomd.bsky.social

Check out the #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (November 25th- December 1st, 2024). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch

Can we bring 2L PFS closer to 12 months post 1L CDK4/6i? More work needed to improve biomarkers for selection of optimal 2L therapeutic option. #ESMOASIA24

Make sure to follow @dfcibreastonc.bsky.social for updates on the latest research efforts by DFCI BOC and for periodic research digest with recent news in breast oncology! @stolaney1.bsky.social

Dr. Abirami Natarajan and Dr. Sara Tolaney (@stolaney1.bsky.social) discuss adjuvant #ribociclib in this Annals of Oncology editorial. 👀 check it out here: sciencedirect.com/science/arti...

Out in @TheLancetOncol De-escalated neoadjuvant CT with trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer PCR rate 66.3% vs. 57.6% in the nab-paclitaxel group vs. in the docetaxel + carbo group @oncoalert.bsky.social www.thelancet.com/journals/lan...

We are looking forward to this year's San Antonio Breast Cancer Symposium which starts on December 10. Take a look at the full program for this important meeting featuring the latest research on breast cancer. sabcs.org/FullProgram #SABCS24 #breastcancer

Link for more info & to access FDA-ASCO Fellows’ Day Workshop application is here: asco.smapply.org/prog/Februar.... Apply by 12/4/24. Hope to see some of you in person or on Zoom for a day of #regulatory science #MedEd, #OncSky! 😃 #MedSky #healthpolicy #mentorship #OncoAlert

Grade 1-2 treatment-related irAEs in the first cycle of therapy were associated with longer overall survival compared to no irAEs from checkpoint inhibitors. #survonc #supponc doi.org/10.1093/jnci...

Looking forward to #SABCS24 - there is a lot of important research being presented, some to highlight: 🔑 Biomarker analysis of KN522 🔑 EMBER-3 🔑 MARGOT 🔑 SONIA 🔑 EUROPA 🔑 SOLTI VALENTINE 🔑 GeparDouze

We are going to be bringing #SABCS24 updates to #BlueSky too starting Dec 10th! Many great colleagues on here including some amazing advocates. @itsnotpink.bsky.social @janicetnbcmets.bsky.social @oncbrothers.bsky.social @hoperugo.bsky.social ....and others! @sabcs.bsky.social #bcsm